Skip to main content

Table 1 Demographic characteristics of patients receiving Kovaltry and EHL

From: Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis

Patient characteristics

All Kovaltry (n = 29)

Prophylactic Kovaltry (n = 22)

Prophylactic EHL (n = 60)

Age group n (%)

   

 0–5 years

5 (17.2)

3 (13.6)

3 (5.0)

 6–11 years

15 (51.7)

11 (50.0)

15 (25.0)

 12–17 years

9 (31.0)

8 (36.4)

42 (70.0)

Body mass index groups

   

 Underweight < 18.5

10 (34.5)

8 (36.4)

9 (15.0)

 Normal 18.5–24.9

9 (31.0)

8 (36.4)

40 (66.7)

 Overweight 25–29.9

5 (17.2)

2 (9.1)

6 (10.0)

 Obese 30+

4 (13.8)

3 (13.6)

4 (6.7)

 Missing

1 (3.4)

1 (4.5)

1 (1.7)

Severity

   

 Moderate (1–5 IU/dL)

2 (6.9)

2 (9.1)

12 (20.0)

 Severe (< 1 IU/dL)

27 (93.1)

20 (90.9)

48 (80.0)

History of inhibitors

   

 0 Never

23 (79.3)

17 (77.3)

46 (76.7)

 1 Once

6 (20.7)

5 (22.7)

10 (16.7)

 More than once—recurrence/relapse

0 (0)

0 (0)

4 (6.70)

Treatment regimen at initiation

   

 Continuous prophylaxis

22 (75.9)

17 (77.3)

24 (40.0)

 Episodic—on demand—treatment

6 (20.7)

3 (13.6)

32 (53.3)

 Intermittent—periodic—prophylaxis

1 (3.4)

2 (9.1)

4 (6.7)

Target joints

   

 No

26 (89.7)

20 (90.9)

49 (81.7)

 Yes

3 (10.3)

2 (9.1)

11 (18.3)

Chronically damaged joints

   

 No

26 (89.1)

21 (95.5)

47 (78.3)

 Yes

3 (10.3)

1 (4.5)

13 (21.7)

Treatment adherence

   

 Fully adherent: missing < 15% of infusions

25 (86.2)

18 (81.8)

51 (85.0)

 Sub-optimally adherent: missing 15–25% of infusions

3 (10.3)

3 (13.6)

7 (11.7)

 Non-adherent: missing > 25% of infusions

0

0

0 (0)

 Not applicable

1 (3.4)

1 (4.5)

2 (3.30)